3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
3
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
7
trametinib
5
pembrolizumab
5
selpercatinib
4
dabrafenib
4
Specimen Handling
4
Nivolumab
4
cabozantinib
3
Iodine-131
3
spartalizumab
2
omipalisib
2
lenvatinib
2
durvalumab
2
binimetinib
2
Vemurafenib
2
Sorafenib
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
CTLA-4 Antigen
2
Biopsy
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
tipifarnib
1
sapanisertib
1
relatlimab
1
regorafenib
1
pertuzumab
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Thyroid Neoplasms
×
naporafenib
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled